GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Shiller PE Ratio

Veru (VERU) Shiller PE Ratio

: (As of Today)
View and export this data going back to 1990. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Veru Shiller PE Ratio Historical Data

The historical data trend for Veru's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.78 57.31 229.22 - -

Veru Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Veru's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Veru's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Veru's Shiller PE Ratio falls into.



Veru Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Veru's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Veru's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.08/129.4194*129.4194
=-0.080

Current CPI (Dec. 2023) = 129.4194.

Veru Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.010 99.695 0.013
201406 0.040 100.560 0.051
201409 -0.020 100.428 -0.026
201412 0.030 99.070 0.039
201503 0.060 99.621 0.078
201506 0.040 100.684 0.051
201509 0.020 100.392 0.026
201512 0.050 99.792 0.065
201603 0.001 100.470 0.001
201606 0.020 101.688 0.025
201609 -0.060 101.861 -0.076
201612 -0.040 101.863 -0.051
201703 -0.060 102.862 -0.075
201706 -0.030 103.349 -0.038
201709 -0.120 104.136 -0.149
201712 -0.080 104.011 -0.100
201803 -0.070 105.290 -0.086
201806 -0.150 106.317 -0.183
201809 -0.140 106.507 -0.170
201812 -0.030 105.998 -0.037
201903 -0.060 107.251 -0.072
201906 -0.040 108.070 -0.048
201909 -0.050 108.329 -0.060
201912 -0.050 108.420 -0.060
202003 -0.010 108.902 -0.012
202006 -0.050 108.767 -0.059
202009 -0.170 109.815 -0.200
202012 0.230 109.897 0.271
202103 -0.040 111.754 -0.046
202106 -0.030 114.631 -0.034
202109 -0.050 115.734 -0.056
202112 -0.080 117.630 -0.088
202203 -0.180 121.301 -0.192
202206 -0.280 125.017 -0.290
202209 -0.510 125.227 -0.527
202212 -0.480 125.222 -0.496
202303 -0.480 127.348 -0.488
202306 -0.080 128.729 -0.080
202309 -0.110 129.860 -0.110
202312 -0.080 129.419 -0.080

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Veru  (NAS:VERU) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Veru Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Veru's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (VERU) Business Description

Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Executives
Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish director, officer: Chairman/Chief Exec. Officer

Veru (VERU) Headlines

From GuruFocus